Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

S. Alice Long, Mary Rieck, Srinath Sanda, Jennifer B. Bollyky, Peter L. Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard, Laurence A. Turka, Mario R. Ehlers, Peter J. Bianchine, Karen D. Boyle, Steven A. Adah, Jeffrey A. Bluestone, Jane H. Buckner, Carla J. Greenbaum

Research output: Contribution to journalArticlepeer-review

220 Scopus citations

Fingerprint

Dive into the research topics of 'Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function'. Together they form a unique fingerprint.

Medicine & Life Sciences